On April 2, 2019, Eli Lilly and Company (“Lilly”) filed a Petition for Post-Grant Review (“PGR”) of Genentech’s U.S. Patent...
Eli Lilly
-
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
-
Posted in:
Genentech Files Suit Alleging Eli Lilly’s Taltz® Product Infringes a Newly Issued Genentech Patent
By Seth Cockrum Comments are off
On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s...
Tagged with: Eli Lilly, Genentech, ixekizumab, News, Taltz®
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with...
Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, eptinezumab, erenumab, FDA, fremanezumab, galcanezumab, News, Novartis, Teva
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
Last week, Novartis and Amgen announced the FDA approved Aimovig™ (erenumab) for the preventive treatment of migraine in adults. The...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
Posted in:
Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes
By Caitlin M. Wilmot Comments are off
Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee™, received marketing...
Tagged with: Abasaglar™, Biocon, Eli Lilly, FDA, Insulin glargine, Lantus®, Lusduna™, Merck, Mylan, Sanofi, Semglee™, trastuzumab
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus